
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is a leader in surgical treatments for cardiac conditions and pain management, with a strong focus on innovation and growth. Their diverse product line and strong sales force position them well for continued double-digit growth, and we anticipate improved profitability in the coming years. Despite trading at a lower EV/sales multiple than its peers, we believe AtriCure's multiple shots on goal in 2026 and beyond justify a higher valuation, leading us to reiterate our market outperform rating with a price target of $52.
Bears say
AtriCure is a company that operates in the medical industry and specializes in surgical treatments for various heart conditions. Despite a strong balance sheet and expected growth in revenue and earnings, we believe the launch of MDT's Penditure LAAC device will result in a significant slowdown in AtriCure's Appendage Management growth, which will negatively impact its profitability and cash flow. As such, we have a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares